Strain Name:

STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J

Stock Number:

008755

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Other products are available, see Purchasing Information for Cryopreserved Embryos

Use Restrictions Apply, see Terms of Use
Mice harboring both the Ins2-rtTA (or RIP7-rtTA) transgene and the tet-DTA (or tetO-DTA) transgene have doxycycline-inducible expression of DTA in pancreatic beta cells; i.e. addition of doxycycline results in ablation of pancreatic beta cells.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Mutant Stock; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
GenerationF5p
Generation Definitions
 
Donating Investigator IMR Colony,   The Jackson Laboratory

Description
This strain was generated by breeding Stock No. 008168 and Stock No. 008250 together at The Jackson Laboratory. The resulting double transgenic colony was established as Stock No. 008755.

The Ins2-rtTA (or RIP7-rtTA) transgene expresses the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat insulin 2 (Ins2) promoter. The tet-DTA (or tetO-DTA) (transgene expresses diphtheria toxin A (DTA) under the control of a tetracycline operator (tetO; also called tetracycline-responsive element (TRE) or tet-operator) and a cytomegalovirus minimal promoter. Mice harboring both of these transgenes has doxycycline-inducible expression of DTA in pancreatic beta cells; i.e. addition of the tetracycline analogue doxycycline (dox) results in ablation of pancreatic beta cells.

Development
This strain was generated by breeding Stock No. 008168 and Stock No. 008250 together at The Jackson Laboratory. The resulting double transgenic colony was established (as Stock No. 008755). This strain was subsequently maintained by breeding mice carrying for both the RIP7-rtTA transgene and tet-DTA transgene together. The genetic background is a mix of C57BL/6, CBA, and outbred ICR.

Control Information

  Control
   None Available
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(Ins2-rtTA)2Efr allele
008250   STOCK Tg(Ins2-rtTA)2Efr/J
View Strains carrying   Tg(Ins2-rtTA)2Efr     (1 strain)

Strains carrying   Tg(tetO-DTA)1Gfi allele
008468   B6.Cg-Tg(tetO-DTA)1Gfi/J
008168   STOCK Tg(tetO-DTA)1Gfi/J
View Strains carrying   Tg(tetO-DTA)1Gfi     (2 strains)

Strains carrying other alleles of Dta
008617   B6(A)-Tg(OPN1LW-DT)1Mame/J
007942   B6.Cg-Isl2tm1Arbr/J
017949   B6.FVB-Tg(CD207-Dta)312Dhka/J
006576   B6.FVB-Tg(GNAT2-Dta)98Wwk/J
002384   FVB/N-Tg(UcpDta)1Kz/J
View Strains carrying other alleles of Dta     (5 strains)

Strains carrying other alleles of Ins2
005534   B10.Cg-H2d Tg(Ins2-HA)165Bri/ShrmJ
005500   B6.C-Tg(Ins2-GP)34-20Olds/MvhJ
005715   B6.Cg H2g7-Tg(Ins2-CD80)3B7Flv/LwnJ
004826   B6.Cg-Tg(Ins2-NP)25-3Olds/MhvJ
003573   B6.Cg-Tg(Ins2-cre)25Mgn/J
018960   B6N.Cg-Tg(Ins2-cre)25Mgn/J
005713   C.Cg-Tg(Ins2-CD80)3B7Flv/LwnJ
005533   C.Cg-Tg(Ins2-HA)165Bri/ShrmJ
004827   C.Cg-Tg(Ins2-NP)25-3Olds/MvhJ
005432   C57BL/6-Tg(Ins2-OVA)307Wehi/WehiJ
005433   C57BL/6-Tg(Ins2-OVA)59Wehi/WehiJ
005431   C57BL/6-Tg(Ins2-TFRC/OVA)296Wehi/WehiJ
005564   FVB(Cg)-Tg(Ins2-CALM1)26Ove Tg(Cryaa-TAg)1Ove/PneJ
008232   FVB/N-Tg(Ins2-IAPP)RHFSoel/J
005522   NOD-Tg(Ins2*Y16A)1Ell/GseJ
005523   NOD-Tg(Ins2*Y16A)3Ell/GseJ
003499   NOD-Tg(Ins2-Fasl)24Ach
004346   NOD.Cg-Prkdcscid Tg(Ins2-CD80)3B7Flv/DvsJ
004230   NOD.Cg-Prkdcscid Tg(Ins2-E3)1Dvs/DvsJ
003843   NOD.Cg-Prkdcscid Tg(Ins2-GAD2)1Lt/LtJ
003844   NOD.Cg-Prkdcscid Tg(Ins2-GAD2)2Lt/LtJ
007840   NOD.Cg-Prkdcscid Tg(Ins2-CD86)12B70Flv/FswJ
005524   NOD.Cg-Tg(Ins2*Y16A)1Ell Ins1tm1Jja Ins2tm1Jja/GseJ
005525   NOD.Cg-Tg(Ins2*Y16A)3Ell Ins1tm1Jja Ins2tm1Jja/GseJ
006254   NOD.Cg-Tg(Ins2-Ccl21b)2Cys/JbsJ
006154   NOD.Cg-Tg(Ins2-Cxcl13)1Cys/JbsJ
003869   NOD.Cg-Tg(Ins2-E3)1Dvs/DvsJ
005685   NOD.Cg-Tg(Ins2-HA)165Bri/ShrmJ
002380   NOD.Cg-Tg(Ins2-TAg)1Lt Prkdcscid/DvsJ
023972   NOD.Cg-Tg(Ins2-cre/ERT)1Dam/SbwJ
004602   NOD.Cg-Tg(Ins2-rtTA)2Doi/DoiJ
004937   NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ
005734   NOD/Lt-Tg(Ins2-rtTA)1Ach/AchJ
005870   NOD/ShiLt(Cg)-Tg(Ins2-GAD2)2Lt/J
006777   NOD/ShiLt-Tg(Ins2-Cd274)2Mdos/MdosJ
005733   NOD/ShiLt-Tg(Ins2-Fas*I246N)1Ach/AchJ
003074   NOD/ShiLt-Tg(Ins2-GAD2)1Lt/LtJ
002033   NOD/ShiLt-Tg(Ins2-TAg)1Lt/J
004986   NOD/ShiLt-Tg(Ins2-cre)3Lt/LtJ
003855   NOD/ShiLt-Tg(Ins2-cre)5Lt/LtJ
004987   NOD/ShiLt-Tg(Ins2-cre)6Lt/LtJ
004226   NOD/ShiLtDvs-Tg(Ins2-E3*309)5Dvs/DvsJ
004227   NOD/ShiLtDvs-Tg(Ins2-E3*704)2Dvs/DvsJ
004968   NOD/ShiLtDvs-Tg(Ins2-E3*734)3Dvs/DvsJ
004990   NOD/ShiLtDvs-Tg(Ins2-E3*734)4Dvs/DvsJ
005714   NOR.Cg-Tg(Ins2-CD80)3B7Flv/LwnJ
008122   STOCK Tg(Ins2-cre/ERT)1Dam/J
View Strains carrying other alleles of Ins2     (47 strains)

Strains carrying other alleles of rtTA
016567   129S.Cg-Tg(Hoxb7-rtTA*M2)2Cos/J
017983   B6.Cg-Col1a1tm9(tetO-Dnmt3b_i1)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
014588   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm6(tetO-MSI2)Jae/J
014602   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-mCherry)Eggn/J
023749   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn/J
006965   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
005670   B6.Cg-Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/J
016997   B6.Cg-Tg(Axin2-rtTA2S*M2)7Cos/J
012418   B6.Cg-Tg(CD68-rtTA2S*M2)3Mpil/Mmjax
014098   B6.Cg-Tg(GFAP-rtTA*M2)1Rmra/J
007176   B6.Cg-Tg(Pax8-rtTA2S*M2)1Koes/J
006235   B6.Cg-Tg(SFTPC-rtTA)5Jaw/J
006232   B6.Cg-Tg(Scgb1a1-rtTA)1Jaw/J
021025   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-cre)Haho/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
016836   B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
021187   B6;FVB-Tg(Pbsn-rtTA*M2)42Xy/J
010574   B6;SJL-Tg(Gh1-rtTA)4-3Jek/J
007678   B6;SJL-Tg(KRT14-rtTA)208Jek/J
010576   B6;SJL-Tg(MMTV-rtTA)4-1Jek/J
010549   B6N.Cg-Tg(Prkcd-glc-1-rtTA)2And/J
016532   B6N.FVB(Cg)-Tg(CAG-rtTA3)4288Slowe/J
006245   C.Cg-Tg(SFTPC-rtTA)5Jaw/J
006242   C.Cg-Tg(Scgb1a1-rtTA)1Jaw/J
017955   C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J
008099   FVB-Tg(KRT14-rtTA)F42Efu/J
004127   FVB-Tg(Nes-rtTA)306Rvs/J
008326   FVB-Tg(Pomc-rtTA)1Rck/J
006225   FVB.Cg-Tg(SFTPC-rtTA)5Jaw/J
006222   FVB.Cg-Tg(Scgb1a1-rtTA)1Jaw/J
008202   FVB/N-Tg(NPHS2-rtTA2*M2)1Jbk/J
006875   FVB/N-Tg(Tagln-rtTA)E1Jwst/J
004602   NOD.Cg-Tg(Ins2-rtTA)2Doi/DoiJ
005734   NOD/Lt-Tg(Ins2-rtTA)1Ach/AchJ
011004   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011011   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011013   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J
005572   STOCK Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/J
016116   STOCK Waptm2(rtTA)Kuw/J
003273   STOCK Tg(CMV-rtTA)4Bjd/J
018156   STOCK Tg(Drd1a-rtTA)ARgmk/J
019110   STOCK Tg(Hoxb7-rtTA*M2)RS40BCos/Mmjax
017519   STOCK Tg(KRT5-rtTA)T2D6Sgkd/J
016146   STOCK Tg(SFTPC-rtTA)2Jaw/J
016145   STOCK Tg(Scgb1a1-rtTA)2Jaw/J
005493   STOCK Tg(Tek-rtTA,TRE-lacZ)1425Tpr/J
View Strains carrying other alleles of rtTA     (47 strains)

Strains carrying other alleles of tetO
008079   129S-Ppargtm2Yba/J
016178   B6(Cg)-Tg(tetO-Cry2)3Jt/J
016176   B6(Cg)-Tg(tetO-Per2)2Jt/J
023757   B6(Cg)-Tg(tetO-tetX,lacZ)1Gogo/UmriJ
009602   B6.129S4(Cg)-Kcnn2tm2Jpad/J
009603   B6.129S4-Kcnn3tm1Jpad/J
023910   B6.Cg-Col1a1tm1(tetO-Lin28a)Gqda/J
023911   B6.Cg-Col1a1tm2(tetO-LIN28B)Gqda/J
023912   B6.Cg-Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/J
017983   B6.Cg-Col1a1tm9(tetO-Dnmt3b_i1)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
014588   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm6(tetO-MSI2)Jae/J
023749   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn/J
014648   B6.Cg-Gt(ROSA)26Sortm37(H1/tetO-RNAi:Taz)Arte/ZkhuJ
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
016998   B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J
003762   B6.Cg-Tg(tetFosb)4468Nes/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
007618   B6.Cg-Tg(tetO-Arntl)1Jt/J
017555   B6.Cg-Tg(tetO-CALY)5Cber/J
024114   B6.Cg-Tg(tetO-CHRM4*)2Blr/J
008277   B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J
017791   B6.Cg-Tg(tetO-Hamp)2181Nca/J
009344   B6.Cg-Tg(tetO-Ifng)184Pop/J
009136   B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
020652   B6.Cg-Tg(tetO-Mif)279Aren/J
017331   B6.Cg-Tg(tetO-Ppp3ca*)11255Kndl/J
017332   B6.Cg-Tg(tetO-Ppp3ca*)13967Kndl/J
017330   B6.Cg-Tg(tetO-TAg*)175Kndl/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
005738   B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J
021025   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-cre)Haho/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
011001   B6;129S4-Col1a1tm1(tetO-Pou5f1,-Klf4,-Sox2,-Myc)Hoch/J
016836   B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
002709   B6;C3-Tg(TettTALuc)1Dgs/J
023598   B6;C3-Tg(tetO-AIMP2)630Tmd/J
023642   B6;C3-Tg(tetO-AIMP2)634Tmd/J
016841   B6;C3-Tg(tetO-TARDBP)12Vle/J
014650   B6;C3-Tg(tetO-TARDBP*)4Vle/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
008344   B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J
024742   B6;DBA-Tg(tetO-GCaMP6s)2Niell/J
024088   B6;FVB-Tg(tetO-AML1/ETO)8Dzh/J
008082   B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J
010575   B6;SJL-Tg(tetO-Egfr*)2-9Jek/J
010577   B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002621   B6;SJL-Tg(tetop-lacZ)2Mam/J
006004   B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
018913   B6N.Cg-Tg(tetO-GFP,-lacZ)G3Rsp/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
017719   C3HeB/FeJ-Tg(tetO-TAg)1Efr/J
017955   C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
017613   C57BL/6-Tg(tetO-Cdkn1b)1Scpr/J
013729   C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J
016260   C57BL/6-Tg(tetO-Fbxl21)38Jt/J
016179   C57BL/6-Tg(tetO-Fbxl21*)11Jt/J
010713   C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J
013728   C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J
016181   C57BL/6-Tg(tetO-Nr1d1)1Schb/J
016581   C57BL/6J-Tg(tetO-Btrc*)1Jt/J
008278   C57BL/6J-Tg(tetO-Clock)1Jt/J
016580   C57BL/6J-Tg(tetO-Usf1)2Jt/J
021065   FVB(C)-Tg(tetO-Npc1/YFP)1Mps/J
017542   FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J
016571   FVB-Tg(Myh6/tetO-Gata6)2Jmol/J
014155   FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J
014153   FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J
014154   FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J
012684   FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J
010580   FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
013777   FVB-Tg(tetO-Cacna1g)1Jmol/J
013778   FVB-Tg(tetO-Cacnb2)1Jmol/J
013779   FVB-Tg(tetO-Cacnb2)2Jmol/J
013780   FVB-Tg(tetO-Cib1)1Jmol/J
010578   FVB-Tg(tetO-Dusp6)1Jmol/J
017333   FVB-Tg(tetO-Gnai2*,-lacZ)382Kndl/J
008685   FVB-Tg(tetO-Kdr*)4377.5Rwng/J
023397   FVB-Tg(tetO-Lmnb1)AF1Yfu/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
008695   FVB-Tg(tetO-MET)23Rwng/J
012387   FVB-Tg(tetO-Ppargc1a)1Dpk/J
012385   FVB-Tg(tetO-Ppargc1b)7Dpk/J
022979   FVB-Tg(tetO-Thbs4)17.7Jmol/J
006439   FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J
019038   FVB.Cg-Tg(tetO-GLI1)10Rup/Mmjax
019039   FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
012459   FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J
005941   FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J
006202   FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J
014547   FVB/N-Tg(tetO-Fasl)BDepa/J
019376   FVB/N-Tg(tetO-MYC)36aBop/J
022938   FVB/N-Tg(tetO-Wnt5a)17Rva/J
003315   FVB/N-Tg(tetORo1-lacZ)3Conk/J
005076   NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ
006999   STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J
011004   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011011   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011013   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J
018999   STOCK Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/J
017596   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J
017597   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J
024854   STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J
012477   STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J
016572   STOCK Tg(Myh6/tetO-Gata4)1Jmol/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
014093   STOCK Tg(tetO-CHRM3*)1Blr/J
008790   STOCK Tg(tetO-DISC1*)1001Plet/J
017755   STOCK Tg(tetO-GCAMP2)12iRyu/J
024509   STOCK Tg(tetO-Gata6)1Abl/J
016970   STOCK Tg(tetO-HCV)1Mlch/Mmjax
005104   STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J
005699   STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J
005728   STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
017918   STOCK Tg(tetO-MAML1*/EGFP)2Akar/J
017599   STOCK Tg(tetO-SMN2,-luc)#aAhmb/J
017600   STOCK Tg(tetO-SMN2,-luc)#bAhmb/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
006224   STOCK Tg(tetO-cre)1Jaw/J
017906   STOCK Tg(tetO-hop/EGFP,-COP4/mCherry)6Kftnk/J
012345   STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Strains carrying other alleles of tetO     (131 strains)

Additional Web Information

Tet Expression Systems

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tg(Ins2-rtTA)2Efr/0 Tg(tetO-DTA)1Gfi/0

        involves: C57BL/6 * CBA
  • endocrine/exocrine gland phenotype
  • *normal* endocrine/exocrine gland phenotype
    • average size of regenerating beta cells is same as original cells   (MGI Ref ID J:127412)
    • abnormal pancreas morphology
      • pancreatic insulin content is reduced by ~85%; after doxycycline withdrawal, pancreatic insulin level return to near control levels   (MGI Ref ID J:127412)
      • abnormal pancreatic beta cell morphology
        • frequency of insulin-positive, glucagons-positive beta cells increases from 1:5500 in controls to 1:1000 beta cells in diabetic transgenic mice   (MGI Ref ID J:127412)
        • permitting doxycycline-treated mice to recover in presence of immunosupressants Sirolimus and Tacrolimus (SirTac) significantly reduces beta cell proliferation and beta cell mass does not increase as it does in absence of immunosupressants; blood glucose levels in treated mice fail to normalize as they do in controls treated with SirTac   (MGI Ref ID J:127412)
        • decreased pancreatic beta cell number
          • 70-80% of beta cells are lost in doxycycline-treated 5-week old double-transgenic mice relative to controls   (MGI Ref ID J:127412)
          • similar results are obtained when beta cells are ablated between birth and five weeks of age; beta cell mass normalizes within ~15 weeks of doxycycline withdrawal   (MGI Ref ID J:127412)
        • increased pancreatic beta cell number
          • rate of beta cell apoptosis in recovering mice is not different from controls, but beta cell proliferation is increased 2-3-fold within 48 hours of onset of beta cell ablation; this increased proliferation rate is maintained for several weeks   (MGI Ref ID J:127412)
      • disorganized pancreatic islets
        • treatment of four-week old mice with doxycycline for 1 week results in severely disrupted islet architecture with non-beta cells at the core of shriveled islets rather than beta cells   (MGI Ref ID J:127412)
        • after withdrawal of doxycycline, normalization of islet architecture occurs in ~90% of islets   (MGI Ref ID J:127412)
  • homeostasis/metabolism phenotype
  • *normal* homeostasis/metabolism phenotype
    • peripheral insulin sensitivity after beta cell regeneration is similar to controls after doxycycline withdrawal, beta cell mass in transgenic mice increases to levels comparable to wild-type   (MGI Ref ID J:127412)
    • improved glucose tolerance
      • after more than 8 months without doxycycline, glucose tolerance starts to recover   (MGI Ref ID J:127412)
      • similar results are obtained when beta cells are ablated between birth and five weeks of age; beta cell mass normalizes within ~15 weeks of doxycycline withdrawal   (MGI Ref ID J:127412)
      • mice that showed severe, chronic or adult-onset (starting at 4 months) hyperglycemia spontaneously normalized blood glucose levels and beta-cell mass after doxycycline withdrawal   (MGI Ref ID J:127412)
    • increased circulating glucose level
      • blood glucose levels of treated mice are elevated to 300-600 mg/dl making the mice overtly diabetic; after withdrawal of doxycycline, blood glucose levels return to normal level   (MGI Ref ID J:127412)
      • mice that showed severe, chronic or adult-onset (starting at 4 months) hyperglycemia spontaneously normalized blood glucose levels and beta-cell mass after doxycycline withdrawal   (MGI Ref ID J:127412)
      • hyperglycemia
        • blood glucose levels are elevated to 300-600 mg/dl; after doxycycline withdrawal, remission of hyperglycemia occurs such that fed and fasting glucose levels normalize   (MGI Ref ID J:127412)
        • mice that showed severe, chronic or adult-onset (starting at 4 months) hyperglycemia spontaneously normalized blood glucose levels and beta-cell mass after doxycycline withdrawal   (MGI Ref ID J:127412)
  • cellular phenotype
  • increased apoptosis
    • widespread pancreatic beta cell apoptosis is seen within 48 hours of doxycycline treatment of double-transgenic mice, but no apoptosis is observed in single transgenic littermates   (MGI Ref ID J:127412)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Diabetes and Obesity Research
Type 1 Diabetes (IDDM)

Endocrine Deficiency Research
Pancreas Defects

Immunology, Inflammation and Autoimmunity Research
Autoimmunity
      Type 1 Diabetes

Metabolism Research
Enzyme Deficiency
      exocrine pancreatic insufficiency

Neurobiology Research
Tet Expression System
      tTA/rtTA Expressing Strains
      tTA/rtTA Responsive Strains

Research Tools
Cancer Research
      Tetop Tet System
Cardiovascular Research
      Tetop Tet System
Diabetes and Obesity Research
Genetics Research
      Mutagenesis and Transgenesis
      Mutagenesis and Transgenesis: Tetop Tet System
      Tissue/Cell Markers
      Tissue/Cell Markers: pancreatic beta cells
Neurobiology Research
      Tetop Tet System
Tet Expression Systems
      tTA/rtTA Expressing Strains
      tTA/rtTA Responsive Strains

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(Ins2-rtTA)2Efr
Allele Name transgene insertion 2, Shimon Efrat
Allele Type Transgenic (Inserted expressed sequence)
Common Name(s) Ins-rtTA; RIP7-rtTA; RiprtTA;
Strain of Origin(C57BL/6 x CBA)F2
Site of Expressionpancreatic beta cells
Expressed Gene rtTA, reverse tetracycline-controlled transactivator, E. coli
The tetracycline repressor gene (Tetr), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). One mutant with a four amino acid residue change (rTetR) exhibited dependence on tetracycline for induction of the targeted gene and was used in the rtTA construct (Gossen et al, 1995). rTetr was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16).
Promoter Ins2, insulin 2, rat
Molecular Note A transgenic construct containing 9.5kb 5' regulatory sequence and first intron of the rat insulin 2 gene (RIP7) controlling the reverse tetracycline transactivator (rtTA), as well as the polyadenylation site sequence of the RIP7 gene was injected into fertilized (C57BL/6 X CBA)F2 mouse eggs. Founder line 2 with 10 copies of the transgene was established. When mice are crossed to transgenic mice carrying reporter genes, transgene expression is detected only in pancreatic islet beta cells. [MGI Ref ID J:130049]
 
 
 
Allele Symbol Tg(tetO-DTA)1Gfi
Allele Name transgene insertion 1, Glenn I Fishman
Allele Type Transgenic (Inducible, Inserted expressed sequence)
Common Name(s) tet-DTA; tetODTA/+;
Strain of Origin(C57BL/6 x CBA)F2
Site of Expressionpancreatic beta cells
Expressed Gene Dta, Diphtheria toxin A chain,
Promoter tetO, tet operator,
Molecular Note A transgenic construct was created, containing diphtheria toxin A sequence (DTA) under the control of heptamerized tetracycline operator, tetO sequences fused to a cytomegalovirus minimal promoter. [MGI Ref ID J:128617]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(tTA), QPCR
Tg(tetO-DTA)1Gfi, QPCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Lee P; Morley G; Huang Q; Fischer A; Seiler S; Horner JW; Factor S; Vaidya D; Jalife J; Fishman GI. 1998. Conditional lineage ablation to model human diseases. Proc Natl Acad Sci U S A 95(19):11371-6. [PubMed: 9736743]  [MGI Ref ID J:128617]

Milo-Landesman D; Surana M; Berkovich I; Compagni A; Christofori G; Fleischer N; Efrat S. 2001. Correction of hyperglycemia in diabetic mice transplanted with reversibly immortalized pancreatic beta cells controlled by the tet-on regulatory system. Cell Transplant 10(7):645-50. [PubMed: 11714200]  [MGI Ref ID J:130049]

Additional References

Tg(Ins2-rtTA)2Efr related

Balcazar N; Sathyamurthy A; Elghazi L; Gould A; Weiss A; Shiojima I; Walsh K; Bernal-Mizrachi E. 2009. mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. J Biol Chem 284(12):7832-42. [PubMed: 19144649]  [MGI Ref ID J:148614]

Berkovich I; Efrat S. 2001. Inducible and Reversible beta-Cell Autoimmunity and Hyperplasia in Transgenic Mice Expressing a Conditional Oncogene. Diabetes 50(10):2260-7. [PubMed: 11574407]  [MGI Ref ID J:71705]

Cai Q; Brissova M; Reinert RB; Pan FC; Brahmachary P; Jeansson M; Shostak A; Radhika A; Poffenberger G; Quaggin SE; Jerome WG; Dumont DJ; Powers AC. 2012. Enhanced expression of VEGF-A in beta cells increases endothelial cell number but impairs islet morphogenesis and beta cell proliferation. Dev Biol 367(1):40-54. [PubMed: 22546694]  [MGI Ref ID J:185806]

De Leu N; Heremans Y; Coppens V; Van Gassen N; Cai Y; D'Hoker J; Magenheim J; Salpeter S; Swisa A; Khalaileh A; Arnold C; Gradwohl G; Van de Casteele M; Keshet E; Dor Y; Heimberg H. 2014. Short-term overexpression of VEGF-A in mouse beta cells indirectly stimulates their proliferation and protects against diabetes. Diabetologia 57(1):140-7. [PubMed: 24121626]  [MGI Ref ID J:206478]

Eldor R; Abel R; Sever D; Sadoun G; Peled A; Sionov R; Melloul D. 2013. Inhibition of nuclear factor-kappaB activation in pancreatic beta-cells has a protective effect on allogeneic pancreatic islet graft survival. PLoS One 8(2):e56924. [PubMed: 23437272]  [MGI Ref ID J:199335]

Eldor R; Yeffet A; Baum K; Doviner V; Amar D; Ben-Neriah Y; Christofori G; Peled A; Carel JC; Boitard C; Klein T; Serup P; Eizirik DL; Melloul D. 2006. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A 103(13):5072-7. [PubMed: 16551748]  [MGI Ref ID J:107655]

Gupta S; McGrath B; Cavener DR. 2009. PERK regulates the proliferation and development of insulin-secreting beta-cell tumors in the endocrine pancreas of mice. PLoS One 4(11):e8008. [PubMed: 19956728]  [MGI Ref ID J:155377]

Hakonen E; Ustinov J; Eizirik DL; Sariola H; Miettinen PJ; Otonkoski T. 2014. In vivo activation of the PI3K-Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes. Diabetologia 57(5):970-9. [PubMed: 24493201]  [MGI Ref ID J:210180]

Jaggi F; Cabrita MA; Perl AK; Christofori G. 2008. Modulation of endocrine pancreas development but not beta-cell carcinogenesis by Sprouty4. Mol Cancer Res 6(3):468-82. [PubMed: 18337453]  [MGI Ref ID J:138091]

Nir T; Melton DA; Dor Y. 2007. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117(9):2553-61. [PubMed: 17786244]  [MGI Ref ID J:127412]

Porat S; Weinberg-Corem N; Tornovsky-Babaey S; Schyr-Ben-Haroush R; Hija A; Stolovich-Rain M; Dadon D; Granot Z; Ben-Hur V; White P; Girard CA; Karni R; Kaestner KH; Ashcroft FM; Magnuson MA; Saada A; Grimsby J; Glaser B; Dor Y. 2011. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metab 13(4):440-9. [PubMed: 21459328]  [MGI Ref ID J:172243]

Pullen TJ; Sylow L; Sun G; Halestrap AP; Richter EA; Rutter GA. 2012. Overexpression of monocarboxylate transporter-1 (SLC16A1) in mouse pancreatic beta-cells leads to relative hyperinsulinism during exercise. Diabetes 61(7):1719-25. [PubMed: 22522610]  [MGI Ref ID J:192583]

Reinert RB; Cai Q; Hong JY; Plank JL; Aamodt K; Prasad N; Aramandla R; Dai C; Levy SE; Pozzi A; Labosky PA; Wright CV; Brissova M; Powers AC. 2014. Vascular endothelial growth factor coordinates islet innervation via vascular scaffolding. Development 141(7):1480-91. [PubMed: 24574008]  [MGI Ref ID J:208409]

Sodir NM; Swigart LB; Karnezis AN; Hanahan D; Evan GI; Soucek L. 2011. Endogenous Myc maintains the tumor microenvironment. Genes Dev 25(9):907-16. [PubMed: 21478273]  [MGI Ref ID J:171447]

Tg(tetO-DTA)1Gfi related

Black SW; Morairty SR; Chen TM; Leung AK; Wisor JP; Yamanaka A; Kilduff TS. 2014. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci 34(19):6485-94. [PubMed: 24806675]  [MGI Ref ID J:211046]

Chi W; Wu E; Morgan BA. 2013. Dermal papilla cell number specifies hair size, shape and cycling and its reduction causes follicular decline. Development 140(8):1676-83. [PubMed: 23487317]  [MGI Ref ID J:195121]

Gheryani N; Coffelt SB; Gartland A; Rumney RM; Kiss-Toth E; Lewis CE; Tozer GM; Greaves DR; Dear TN; Miller G. 2013. Generation of a novel mouse model for the inducible depletion of macrophages in vivo. Genesis 51(1):41-9. [PubMed: 22927121]  [MGI Ref ID J:207362]

Nir T; Melton DA; Dor Y. 2007. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117(9):2553-61. [PubMed: 17786244]  [MGI Ref ID J:127412]

Porat S; Weinberg-Corem N; Tornovsky-Babaey S; Schyr-Ben-Haroush R; Hija A; Stolovich-Rain M; Dadon D; Granot Z; Ben-Hur V; White P; Girard CA; Karni R; Kaestner KH; Ashcroft FM; Magnuson MA; Saada A; Grimsby J; Glaser B; Dor Y. 2011. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metab 13(4):440-9. [PubMed: 21459328]  [MGI Ref ID J:172243]

Stanger BZ; Tanaka AJ; Melton DA. 2007. Organ size is limited by the number of embryonic progenitor cells in the pancreas but not the liver. Nature 445(7130):886-91. [PubMed: 17259975]  [MGI Ref ID J:118596]

Tabuchi S; Tsunematsu T; Black SW; Tominaga M; Maruyama M; Takagi K; Minokoshi Y; Sakurai T; Kilduff TS; Yamanaka A. 2014. Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 34(19):6495-509. [PubMed: 24806676]  [MGI Ref ID J:211045]

Wei W; Zeve D; Wang X; Du Y; Tang W; Dechow PC; Graff JM; Wan Y. 2011. Osteoclast progenitors reside in the peroxisome proliferator-activated receptor gamma-expressing bone marrow cell population. Mol Cell Biol 31(23):4692-705. [PubMed: 21947280]  [MGI Ref ID J:178880]

Yamasaki TR; Blurton-Jones M; Morrissette DA; Kitazawa M; Oddo S; LaFerla FM. 2007. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 27(44):11925-33. [PubMed: 17978032]  [MGI Ref ID J:127469]

Yeung ST; Myczek K; Kang AP; Chabrier MA; Baglietto-Vargas D; Laferla FM. 2014. Impact of hippocampal neuronal ablation on neurogenesis and cognition in the aged brain. Neuroscience 259:214-22. [PubMed: 24316470]  [MGI Ref ID J:207913]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryThis strain was generated by breeding Stock No. 008168 and Stock No. 008250 together at The Jackson Laboratory. The resulting double transgenic colony was established (as Stock No. 008755). This strain was subsequently maintained by breeding mice carrying both the RIP7-rtTA transgene and tet-DTA transgene together. The genetic background is a mix of C57BL/6, CBA, and outbred ICR.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Frozen Products

Price (US dollars $)
Frozen Embryo $1650.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Frozen Products

Price (US dollars $)
Frozen Embryo $2145.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   None Available
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)